Piclidenoson is used for the treatment of patients with moderate to severe psoriasis. Credit: Eszter Miller from Pixabay.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted positive opinion for Can-Fite BioPharma’s registration plan submission for Phase III trial of Piclidenoson for the treatment of patients with moderate to severe psoriasis.

The agency has accepted the pivotal trial and the safety of the 3mg dose of Piclidenoson given two times a day.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Can-Fite plans to commence the prospective, double-blind, placebo-controlled and randomised trial of Piclidenoson to demonstrate its clinical efficacy and safety.

This will help the company submit a marketing authorization application.

Can-Fite CEO Dr Pnina Fishman said: “Piclidenoson’s oral dosage and excellent safety record combined with its progressive effectiveness over time make it ideally suited for the treatment of psoriasis, a chronic disease.

“Should this market registration study produce positive results similar to our COMFORT study, we believe Piclidenoson will be well positioned in a very large market which needs more safe and effective oral drug options.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company’s COMFORT study of Piclidenoson was found to meet its primary endpoint with statistically significant improvement against placebo in patients with psoriasis.

The Phase III multicentre, randomised, placebo- and active-controlled, double-blind study evaluated the efficacy and safety of the therapy in over 400 adult patients with moderate to severe plaque psoriasis.

It also showed excellent safety profile in psoriasis patients.

The company has also submitted the chemistry, manufacturing, and controls (CMC), nonclinical data, and clinical pharmacology data to the agency.

In addition, it is submitting a comparable data package to the US Food and Drug Administration (FDA).

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact